201 related articles for article (PubMed ID: 8719036)
1. A VIP hybrid antagonist: from developmental neurobiology to clinical applications.
Gozes I; Fridkin M; Brenneman DE
Cell Mol Neurobiol; 1995 Dec; 15(6):675-87. PubMed ID: 8719036
[TBL] [Abstract][Full Text] [Related]
2. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE
J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331
[TBL] [Abstract][Full Text] [Related]
3. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.
Gozes I; Lilling G; Glazer R; Ticher A; Ashkenazi IE; Davidson A; Rubinraut S; Fridkin M; Brenneman DE
J Pharmacol Exp Ther; 1995 Apr; 273(1):161-7. PubMed ID: 7714762
[TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.
Gozes I; Meltzer E; Rubinrout S; Brenneman DE; Fridkin M
Endocrinology; 1989 Dec; 125(6):2945-9. PubMed ID: 2583049
[TBL] [Abstract][Full Text] [Related]
5. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.
Gressens P; Hill JM; Paindaveine B; Gozes I; Fridkin M; Brenneman DE
J Clin Invest; 1994 Nov; 94(5):2020-7. PubMed ID: 7962548
[TBL] [Abstract][Full Text] [Related]
6. Growth factor properties of VIP during early brain development. Whole embryo culture and in vivo studies.
Gressens P; Paindaveine B; Hill JM; Brenneman DE; Evrard P
Ann N Y Acad Sci; 1997 Apr; 814():152-60. PubMed ID: 9160967
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human neuroblastoma growth by a specific VIP antagonist.
Lilling G; Wollman Y; Goldstein MN; Rubinraut S; Fridkin M; Brenneman DE; Gozes I
J Mol Neurosci; 1994-1995; 5(4):231-9. PubMed ID: 7577366
[TBL] [Abstract][Full Text] [Related]
8. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
9. A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes.
Gozes Y; Brenneman DE; Fridkin M; Asofsky R; Gozes I
Brain Res; 1991 Feb; 540(1-2):319-21. PubMed ID: 1647246
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo treatment of colon cancer by VIP antagonists.
Levy A; Gal R; Granoth R; Dreznik Z; Fridkin M; Gozes I
Regul Pept; 2002 Nov; 109(1-3):127-33. PubMed ID: 12409224
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring.
Hill JM; Cuasay K; Abebe DT
Exp Neurol; 2007 Jul; 206(1):101-13. PubMed ID: 17521630
[TBL] [Abstract][Full Text] [Related]
12. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
13. VPAC receptor signaling modulates grouping behavior and social responses to contextual novelty in a gregarious finch: a role for a putative prefrontal cortex homologue.
Kingsbury MA; Miller KM; Goodson JL
Horm Behav; 2013 Aug; 64(3):511-8. PubMed ID: 23899763
[TBL] [Abstract][Full Text] [Related]
14. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis.
Zupan V; Hill JM; Brenneman DE; Gozes I; Fridkin M; Robberecht P; Evrard P; Gressens P
J Neurochem; 1998 May; 70(5):2165-73. PubMed ID: 9572304
[TBL] [Abstract][Full Text] [Related]
15. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
16. Activation of 5-HT1P receptors on submucosal afferents subsequently triggers VIP neurons and chloride secretion in the guinea-pig colon.
Cooke HJ; Sidhu M; Wang YZ
J Auton Nerv Syst; 1997 Sep; 66(1-2):105-10. PubMed ID: 9335000
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons.
Voss U; Sand E; Hellström PM; Ekblad E
BMC Gastroenterol; 2012 Apr; 12():30. PubMed ID: 22463807
[TBL] [Abstract][Full Text] [Related]
19. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
[TBL] [Abstract][Full Text] [Related]
20. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.
Dufes C; Alleaume C; Montoni A; Olivier JC; Muller JM
J Mol Neurosci; 2003; 21(2):91-102. PubMed ID: 14593209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
